Monday, December 29, 2014

Abiraterone acetate

Abiraterone acetate (ZYTIGA®, Janssen) with prednisone/prednisolone after androgen deprivation therapy failure in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) significantly extends life compared with prednisone/prednisolone alone.1
Statistically significant new data from the final analysis of the COU-AA-302 trial including 4 years of follow-up1 were reported at the 2014 Annual Meeting of the European Society for Medical Oncology.

The findings, presented by Charles Ryan, MD, show an unmatched overall survival of 34.7 months with ZYTIGA® plus prednisone/prednisolone compared with 30.3 months for prednisone/prednisolone alone, providing an unrivalled 4.4 months extension of life. The pre-specified final analysis was performed after 96% of expected deaths had occurred.1



Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More

Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review